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Rat aortic vascular smooth muscle cells (VSMCs) were transfected with a vector encoding a truncated human PDGF/I receptor or the full-length 
human PDGFB receptor. Cells stably expressing the truncated human PDGFJI receptor or the full-length human PDGFB receptor were selected 
and the effect of PDGF BB on DNA synthesis in these cells was studied. Cells expressing the full-length PDGF/I receptor entered DNA synthesis 
normally, however, cells expressing the truncated PDGF/3 receptor failed to enter DNA synthesis in response to PDGF BB. These data show that 
the mitogenic response of rat aortic vascular smooth muscle cells to PDGF BB can be inhibited by the expression of a truncated PDGFB receptor. 
Platelet-derived growth factor; Truncated receptor; Vascular smooth muscle cell 
1. INTRODUCTION 
The role of platelet-derived growth factor (PDGF) in 
the migration and proliferation of vascular smooth 
muscle cells (VSMCs) following endothelial injury re- 
mains uncertain [1,2]. To establish any role in vivo for 
PDGF it is necessary either to neutralise the en- 
dogenous PDGF or to block the receptor through 
which it signals. PDGF initiates mitogenesis through its 
interaction with the extracellular domain of the PDGF 
receptor [3,4]. This interaction has been shown to result 
in the dimerisation of PDGF receptor monomers with 
a subsequent increase in tyrosine kinase activity [5-71. 
The monomers of the complex cross-phosphorylate 
each other on tyrosine residues [8] and this leads to the 
binding to the PDGF receptor dimer and tyrosine phos- 
phorylation of other substrates (e.g. GTPase activating 
protein, phosphatidylinositol-3-kinase and phospholip- 
ase Cy [7,9-131). 
The aim of this study was to determine whether ec- 
topic expression of a truncated PDGF /I receptor in rat 
aortic VSMCs could inhibit PDGF BB-mediated cellu- 
lar events in vitro. A gene encoding the human PDGFB 
receptor truncated in the tyrosine kinase 2 domain was 
generated and expressed in cultured rat aortic VSMCs 
and the effect of expression of this gene on DNA synthe- 
sis was studied. 
2. MATERIALS AND METHODS 
2.1. Generation and sequencing of truncated PDGF receptor vector 
Ueno et al. [14] demonstrated that a truncated 
PDGFB receptor lacking most of the cytoplasmic do- 
main would form a non-functional dimer with the wild 
type PDGFB receptor upon ligand binding. Expression 
of a truncated PDGFB receptor in VSMCs may there- 
fore provide a mechanism by which the PDGF sig- 
nalling pathway can be inhibited sufficiently to prevent 
DNA synthesis in response to PDGF BB. 
A vector for expression of a truncated PDGFfi receptor in VSMCs 
was constructed from the vector PDGFR/?SVIID [15]. This plasmid 
was digested with BamHI and a 5.3 kb fragment containing the N- 
terminal portion of the receptor cDNA was isolated from low melting 
point agarose. The DNA fragment was then recircularised and, fol- 
lowing transformation, an appropriate clone was selected by plasmid 
mapping. The sequence was confirmed by cloning an EcoRI-HpaI 
fragment into bluescript KS+ and sequencing the new join between 
the PDGF receptor cDNA and the SV40 termination sequence using 
double stranded dideoxy sequencing. A diagramatic representation of 
the proteins coded for by the full-length and truncated receptor vec- 
tors is given in Fig. 1. All procedures were carried as described in 
Sambrook et al. [16]. All the enzymes used in cloning were obtained 
from LKB-Phatmacia. 
2.2. Transfection and selection of cells 
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Abbreviations: PDGF, platelet-derived growth factor; VSMC, vascu- 
lar smooth muscle cell; DMEM, Dulbecco’s modification of Eagle’s 
medium; FCS, foetal calf serum; BSA, bovine serum albumin; BrdU, 
bromodeoxyuridine. 
Subcultured VSMCs from adult rat aortae were derived as de- 
scribed [17] grown in Dulbecco’s modification of Eagle’s medium 
(DMEM) supplemented with penicillin and streptomycin + 10% foetal 
calf serum (FCS) and passaged 1:2 every 4 days. For transfection, cells 
between the 8th and 10th passage were grown to approximately 80% 
confluence then harvested by trypsinisation and the trypsin quenched 
by resuspending the cells in DMEM + 10% FCS. The cells were spun 
down and resuspended inelectroporation buffer (NaCl, 137 mM; KCl, 
5 mM; Na,HPO,, 0.7 mM; HEPES, 25 mM (pH 7.05); dextrose 6 mM; 
and salmon sperm DNA, 300 pg. ml-‘) at 3 x lo6 cells . ml-‘. The 
suspension (0.8 ml) was put into electroporation cuvettes (Bio-Rad) 
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with 40 pug of PDGFB receptor plasmid DNA and 5 pg of SVZneo 
DNA and electroporated at 280 V and 960 pF. The cells were allowed 
to recover for 10 min before being added to DMEM + 10% FCS (9.2 
ml) and plated into 75 cm* flasks. Approximately 12% of the cells 
survive this electroporation procedure. Cells were grown in 400 
pug. ml-’ geneticin for two weeks before the geneticin concentration 
was reduced to 200 pug. ml-‘. Cells were subcultured every week for 
the first 3 weeks and then every 4 days. 
2.3. Immunocytochemistry and Northern analysis 
Cells were plated into 96-well plates for immunocytochemistry or
onto 13 mm glass coverslips for immunofluorescence and grown for 
2 days. After a 6 h serum deprivation the cells were washed 3 times 
with phosphate-buffered saline (PBS: NaCl, 137 mM; Na,HPO,, 8.1 
mM; KH,PO,, 1.5 mM; KCl, 2.7 mM pH 7.4) before being fixed with 
4% paraformaldehyde in PBS for 10 min. After tixing the cells were 
washed 3 times for 3 min with PBS before incubation with anti human 
PDGFB receptor antibody (PR7212) [18] at 4Opg. ml-’ in PBS + 3% 
bovine serum albumin (BSA, Sigma) overnight. After washing with 
PBS (3 times for 3 min), cells for peroxidase staining were incubated 
with peroxidase conjugated antimouse IgG antibody raised in goat 
(Sigma), diluted 1:200 in PBS + 3% BSA, for 2 h prior to washing and 
staining with diaminobenzidine. Cells for immunofluorescence were 
incubated with biotin conjugated antimouse IgG raised in goat 
(Sigma) diluted 1:500 for 2 h. After washing the cells (3 times for 3 min 
with PBS) fluoroscein isothiocyanate conjugated to streptavidin was 
added in PBS + 3% BSA for 1 h. The cells were then washed in PBS 
and photographed using a Nikon epifluorescence microscope linked 
to a Joyce Loebel image analysis system. 
Cytoplasmic RNA extraction and Northern analysis was carried 
out as described in Kemp et al. [19] using the cDNA of the extracellu- 
lar domain of the human PDGF receptor as a probe. 
2.4. DNA synthesis 
DNA synthesis was assayed by bromodeoxyuridine (BrdU) incor- 
poration using Amersham Kit RPN 20. Cells were subcultured 1:4 into 
96-well plates and grown for 2 days prior to being washed 3 times in 
PBS and put into serum free DMEM for 48 h. Cells were stimulated 
with recombinant PDGF BB (recombinant homodimer, Penmnsular) 
at 0, 10, 100 and 200 ng .ml-’ or 10% FCS. Bromodeoxyuridine was 
added 18 h after stimulation and the cells were fixed and stained 6 h 
later. This period was chosen because it coincided with peak DNA 
synthesis in these cells in response to PDGF BB. The assay was carried 
out as described in the manufacturers instructions. 
3. RESULTS AND DISCUSSION 
3.1. Expression of the full-length and truncated human 
PDGF receptors 
Expression of the full-length and truncated human 
PDGFj? receptors in rat aortic VSMCs after 3 weeks of 
selection in geneticin, was demonstrated by Northern 
analysis and immunofluorescence. Northern analysis of 
RNA from cells transfected with the truncated PDGFB 
receptor gene showed two RNA species hybridising to 
a cDNA encoding the extracellular domain of the 
human PDGFj? receptor, one of approximately 5 kb, 
a 1 2 3 
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Fig. 2. (a) Northern analysis of cytoplasmic RNA from transfected 
VSMCs. RNA was prepared as described in section 2 and probed 
using the a cDNA encoding the extracellular domain of the human 
PDGF receptor. Lane 1, VSMCs transfected with SV2neo alone show 
one band of approximately 5 kb due to expression of the rat receptor 
gene; lane 2, VSMCs transfected with the full-length PDGF/J receptor 
gene and SV2neo show one band of approximately 5kb due to expres- 
sion of both the full-length human and rat receptor genes; lane 3, 
VSMCs transfected with the truncated PDGFB receptor gene and 
SV2neo show two bands one of approximately 5 kb due to expression 
of the full-length rat receptor gene and one of approximately 3kb due 
to expression of the truncated human receptor gene. The positions of 
the 18s and 28s rRNAs are marked. (b) Ethidium bromide staining 
of the 18s rRNA in the gel prior to transfer. 
similar to that found in RNA from transfected rat aortic 
VSMCs transfected with the SV2neo vector alone, and 
one of approximately 3 kb corresponding to the ex- 
pected size of the truncated human PDGF/3 receptor 
mRNA (Fig. 2). Analysis of RNA from cells transfected 
with the full-length human receptor showed one broad 
band at approximately 5 kb due to both human full- 
length and rat wild type PDGFjI receptor gene expres- 
sion. Expression of the endogenous rat receptor was not 
affected by transfection with the truncated PDGFB re- 
ceptor vector and SV2neo compared with transfection 
with SV2neo alone (Fig. 2). In cells transfected with the 
full-length receptor vector and SV2neo the amount of 
PDGFj? receptor mRNA was increased, relative to total 
RNA levels, presumably due to expression both the 
human and rat receptor genes (Fig. 2). 
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Fig. 1. Size and domain composition of the receptor constructs. TKl, tyrosine kinase 1 domain; TK2, tyrosine kinase 2 domain; KI, kinase insert 
sequence. 
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Fig. 3. Immunofluorescence of rat aortic VSMCs expressing the human PDGFB receptor. (a) VSMCs transfected with SV2neo alone. (b) VSMCs 
transfected with the truncated PDGFB receptor gene and SV2neo. (c) VSMCs transfected with the full-length PDGFB receptor gene and SVZneo. 
The production of the human PDGFB receptor pro- 
tein was examined by immunocytochemical staining of 
cell surface proteins using an anti-human PDGF/? re- 
ceptor antibody (PR7212, [18]) which recognises the 
human PDGF/? receptor with much higher affinity than 
the rat PDGFB receptor. Cells expressing either the 
full-length human PDGF/? receptor or the truncated 
PDGFB receptor showed increased binding of the anti- 
body PR7212 compared with wild-type rat cells (Fig. 3). 
These studies indicated that both the full-length and 
truncated human PDGF/? receptor mRNAs were trans- 
lated. Furthermore, since the cells were not permeabil- 
ised by the fixation procedure only transfected receptor 
proteins localised on the cell surface were detected. 
Thus the data indicate that the rat cells correctly proc- 
essed and targetted the human receptor protein to the 
cell surface (Fig. 3). 
3.2. Effects of the truncated andfull-length uman recep- 
tors on DNA synthesis in VSMCs 
The DNA synthesis response of subcultured rat aor- 
tic VSMCs to stimulation with PDGF BB stimulation 
was determined by BrdU incorporation into DNA (Fig. 
4). The number of nuclei synthesizing DNA during the 
BrdU pulse increased in a dose dependent manner in 
response to PDGF BB reaching half-maximal stimula- 
tion at approximately 7 ng * ml-’ and maximal stimula- 
tion between 10 and 50 ng * ml-’ (Fig. 4). This is consis- 
tent with the data of Kawahara et al. [20] who found 
half maximal stimulation of DNA synthesis by 4 
ng *ml-’ PDGF BB and maximal stimulation by 
25 ng . ml-’ in VSMCs. Transfection of the cells with the 
SV2neo vector alone and selection of the cells in genet- 
icin showed a similar response to PDGF BB to the 
untransfected VSMCs but had a slightly increased back- 
ground level of DNA synthesis (17% in the absence of 
added mitogen increasing to 36% in the presence of 10 
ng * ml-’ PDGF BB). 
VSMCs expressing the truncated PDGFB receptor 
were stimulated with PDGF BB or 10% FCS. Fig. 5 
shows that in the absence of added mitogen approxi- 
mately 13 f 1.2% of the VSMCs expressing the trun- 
cated PDGFB receptor were in DNA synthesis during 
the BrdU pulse. This proportion was not increased by 
the addition of up to 200 ng *ml-’ PDGF BB. By con- 
trast, in the presence of 10% FCS 60 & 3% of the cells 
were in DNA synthesis during the same period. These 
observations indicate that the cells were unable to re- 
spond to PDGF BB although they were able to synthe- 
size DNA in response to serum. The data therefore 
suggest that sufticient runcated receptor was produced 
by the cells to prevent the normal signal transduction 
response to PDGF BB. Since there was no increase in 
the percentage of cells in DNA synthesis at concentra- 
tions of PDGF BB up to 200 ng *ml-’ the major mech- 
anism of inhibition of PDGF signalling was likely to 
ap “t 100 
[PDGF] (nglml) 
Fig. 4. DNA synthesis dose response curve for untransfected VSMCs 
to PDGF BB. Passaged VSMCs were subcultured 1:4 into 96 well 
plates and grown for 2 days. The cells were then washed with serum 
free DMEM and incubated for 48 h in the absence of serum. The cells 
were then restimulated with serum free DMEM + PDGF (0, 5, 10,50, 
100 ng . ml-‘). BrdU was added to the cells for 6 h between 18 and 
24 h after restimulation. The cells were hxed and stained for BrdU 
incorporation at the end of the BrdU pulse. Data are presented as 
mean f S.E.M. (n = 4 counts of BrDu stained nuclei). 
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Fig. 5. DNA synthesis dose response for transfected VSMCs to PDGF BB. VSMCs stably expressing the full-length or truncated human PDGF/3 
receptor quiesced as described above were restimulated with PDGF BB (at 0,lO 100 and 200 ng . ml-‘) or lO%FCS and DNA synthesis was assayed 
by the incorporation of BrdU between 18 and 24 h as described in section 2. Data are presented as mean f S.E.M. (n = 4 counts of BrdU stained 
nuclei). Data are typical of 3 separate xperiments. Cells from truncated line 2 were only stimulated at 0, 10 and 100 ng . ml-’ PDGF BB. 
have been heterodimer formation of the truncated re- 
ceptor with the wild type receptor, causing a reduction 
in I’,, by competition of the inactive receptor for the 
available PDGF BB and not by depletion of the PDGF 
BB from the medium which would have resulted in an 
increase in apparent K,. 
In the absence of added mitogen the proportion of 
cells expressing the full-length human PDGFjI receptor 
which were in DNA synthesis during the BrdU pulse 
was 12 & 1% (Fig. 5). This proportion was increased to 
27 f l%, 38 ? 1% and 42 + 7% by addition of 10 
ng * ml-‘, 100 ng . ml-’ and 200 ng . ml-’ PDGF BB, re- 
spectively (Fig. 5). In response to lO%FCS the percent- 
age of these cells in DNA synthesis to increased to 
73 f 3%. Taken together these results show that expres- 
sion of the full- length human PDGFB receptor did not 
effect PDGF BB induced DNA synthesis in rat VSMCs 
but cells expressing a truncated human PDGFB recep- 
tor were unable to synthesize DNA in response to 
PDGF BB. 
The cell line expressing the truncated PDGF/? recep- 
tor, described above, grew with the normal spindle 
shaped morphology of passaged VSMCs and all were 
grown under the same conditions. However, this cell 
line is derived from a selected population of cells and 
it is possible that the selection generated a cell line with 
a reduced dependence on and/or ability to respond to 
PDGF BB independent of truncated receptor expres- 
sion. A second cell line expressing the truncated human 
PDGFB receptor was therefore generated and the DNA 
synthesis response of this cell line to PDGF BB was 
analysed by BrdU incorporation. These cells showed a 
small increase in the proportion of nuclei synthesizing 
DNA in response to PDGF BB from 15 f 2% in the 
absence of mitogen to 21 + 2% and 24 + 1% in the pres- 
ence of 10 ng * ml-’ and 100 ng . ml-’ PDGF BB, respec- 
tively (Fig. 5). However, the increase in the proportion 
of nuclei synthesizing DNA was inhibited by 60% in the 
presence of 10 ng . ml-’ PDGF BB and 69% in the pres- 
ence of 100 ng . ml-’ PDGF BB when compared with 
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cells not expressing the truncated receptor (n = 4 counts 
of BrdU stained nuclei from each of 2 separate experi- 
ments). The maximum response to PDGF BB in this cell 
line was reached by the addition of between 10 and 50 
ng . ml-’ suggesting that again the mechanism was a 
reduction in the total available active PDGFB receptors 
by heterodimer formation. The difference between the 
results obtained from the two different cell lines express- 
ing the truncated human PDGFj? receptor is likely to 
be due to a lower ratio of the truncated human PDGFjI 
receptor to the wild type rat PDGF/? receptor in the 
second cell line resulting in some residual signalling, 
however, this possibility has not been investigated. 
In conclusion, the data presented in this study dem- 
onstrate that rat aortic VSMCs will correctly process 
and target to the cell membrane the protein for the 
human PDGFjI receptor and a truncated form of this 
gene. Expression of the full-length human gene had no 
effect on the response to PDGF BB of the cells whereas 
expression of the truncated PDGFB receptor gene oc- 
curred at a level sufficient to block or inhibit the cells 
from entering DNA synthesis assayed by BrdU incor- 
poration. 
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